

Ana C Garrido-Castro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5262502/publications.pdf>

Version: 2024-02-01

14
papers

1,903
citations

1040056

9
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

3374
citing authors

#	ARTICLE	IF	CITATIONS
1	Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. <i>Cancer Discovery</i> , 2019, 9, 176-198.	9.4	778
2	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	7.1	753
3	Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2565-2572.	7.0	138
4	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	5.0	60
5	CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure. <i>Current Breast Cancer Reports</i> , 2017, 9, 26-33.	1.0	55
6	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	7.0	37
7	Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1105-1118.	7.0	24
8	Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 5300-5314.	0.9	22
9	Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing. <i>JCO Precision Oncology</i> , 2020, 4, 1084-1097.	3.0	11
10	Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. <i>ESMO Open</i> , 2019, 4, e000444.	4.5	8
11	Predicting breast cancer therapeutic response. <i>Nature Medicine</i> , 2018, 24, 535-537.	30.7	6
12	Understanding resistance to immune checkpoint inhibitors in advanced breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 141-153.	2.4	5
13	Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 449-455.	1.3	3
14	PD-L1 Testing in Patients with Breast Cancer: Controversies and Current Practice. <i>Current Breast Cancer Reports</i> , 2019, 11, 353-357.	1.0	2